These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
- Applied Genetic Technologies (AGTC), 1,631% surge in interest
- Sutro Biopharma (STRO), 1,177% surge in interest
- Regenxbio (RGNX), 426% surge in interest
- Fortress Biotech (FBIO), 280% surge in interest
- Cyclerion Therapeutics (CYCN), 185% surge in interest
Pipeline and key clinical candidates for these companies:
Applied Genetic Technologies is developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system diseases. AGTC’s most advanced clinical programs in XLRP and ACHM CNGB3 leverage its technology platform to potentially improve vision for patients with inherited retinal diseases. Its preclinical programs build on AGTC’s AAV manufacturing technology and scientific expertise. Earlier this week, Applied Genetic announced an agreement pursuant to which a newly established portfolio company of Syncona will acquire AGTC through a tender offer for approximately $23.5M, or 34c per share, in cash.
Sutro Biopharma is pioneering site-specific and novel-format antibody drug conjugates, or ADCs. Sutro has two wholly owned ADCs in the clinic – STRO-002, a folate receptor alpha-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies.
Regenxbio is exploring the curative potential of gene therapy. Regenxbio’s NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. Regenxbio and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas.
Fortress Biotech is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has nine marketed prescription pharmaceutical products and over 30 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy.
Cyclerion Therapeutics is working to develop treatments for mitochondrial diseases, including MELAS. Cyclerion’s lead molecule is CY6463, a novel, first-in-class, CNS-penetrant sGC stimulator that modulates a key node in a fundamental signaling network. CY6463 is currently in clinical development for MELAS where it has shown rapid improvement in multiple disease-relevant biomarkers, the company says.
Recent news on these stocks:
October 24
Applied Genetic announced that it has entered into a definitive agreement pursuant to which a newly established portfolio company of Syncona, will acquire AGTC, through a tender offer, for approximately $23.5M, or 34c per share, in cash at the closing of the transaction plus potential future aggregate cash payments of up to $50M pursuant to contingent value rights, or CVRs. The board of directors of AGTC unanimously recommended that the shareholders of AGTC tender their shares in the tender offer once it is commenced.
Sutro Biopharma announced that Chief Medical Officer, Arturo Molina, M.D., M.S., F.A.C.P. will be leaving the company to pursue other opportunities, effective November 4, 2022. Sutro will continue its executive search for a new CMO. In the interim, Bill Newell CEO, with support from Sutro’s senior clinical development team, will oversee all clinical activities and related functions.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CYCN:
